Patents Represented by Attorney Daniel B. Moran

Find this attorney in the Justia Lawyer Directory

  • Glycopeptide antibiotics
    Patent number: 6914045
    Abstract: The invention provides compounds of formula Wherein R1, R2, R3, R4, R5, R6a, R6b, R6c, R6d, R6e and R7 are defined in the specification. These compounds are useful as antibiotic agents.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: July 5, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Darren Robert Abbanat, Valerie Sue Bernan, Russell George Dushin, Michael Greenstein, Haiyin He, Stanley Albert Lang, Howard Newman, Subas Sakya, Phaik-Eng Sum, Alan Gordon Sutherland, Ting-Zhong Wang, Jason Arnold Lotvin, Mark Edward Ruppen, Arthur Emergy Bailey, Ping Cai, Bo Shen, Fangming Kong
  • Compositions containing pipercillin and tazobactam useful for injection
    Patent number: 6900184
    Abstract: The invention pertains to pharmaceutical compositions of Zosyn® piperacillin with tazobactam in the presence of a buffer, preferably citrate, a particulate formation inhibitor, preferably EDTA optionally an aminoglycoside which when frozen and thawed or lyophilized and reconstituted reform a solution which has decreased particulate formation.
    Type: Grant
    Filed: April 14, 2003
    Date of Patent: May 31, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Jonathan Marc Cohen, Syed M. Shah, Christian Luther Ofslager, Mahdi Fawzi
  • Reversal of multidrug resistance in human colon carcinoma cells
    Patent number: 6878737
    Abstract: The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: April 12, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Sridhar Krishna Rabindran, Haiyin He, Lee Martin Greenberger
  • 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
    Patent number: 6861445
    Abstract: The invention relates to compounds of Formula (I), to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: March 1, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Joseph William Epstein, Semiramis Ayral-Kaloustian
  • Antibiotic AA 896 analogs
    Patent number: 6858591
    Abstract: The invention provides compounds of the Formula 1 wherein the definitions of m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 are in the specification. These compounds are useful as antibacterial agents.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: February 22, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Ayako Yamashita, Emily Boucher Norton
  • Antibiotic cytosporacin
    Patent number: 6784204
    Abstract: This disclosure describes new antibiotic Cytosporacin having the structure: The invention relates to a new antibiotic designated Cytosporacin, to its production by fermentation, to methods for its recovery and concentration from the crude solutions, and to process for its purification. The invention includes within its scope the agent in dilute form, as a crude concentrate, and in pure form. The invention also relates to the use of the compound according to the invention in antimicrobial compositions and as antiseptics or disinfectants.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: August 31, 2004
    Assignee: Wyeth Holdings Corporation, Five Giralda Farms
    Inventors: Haiyin He, Jeffrey Edwin Janso
  • 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
    Patent number: 6784184
    Abstract: This invention relates to a method of using novel 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones of Formula (I), wherein Ar, Ar′, R6, m and n are as defined in the specification as inhibitors of Ras FPTase, and may be used as an alternative to, or in conjunction with, traditional cancer therapy for treating ras-oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: August 31, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Joseph William Epstein, Semiramis Ayral-Kaloustian, Gary Harold Birnberg, Edward James Salaski, Gloria Jean Macewan, Katherine Cheung
  • 3-substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
    Patent number: 6740675
    Abstract: The invention relates to compounds of Formula (I), to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: May 25, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Joseph William Epstein, Semiramis Ayral-Kaloustian
  • Nucleoside peptide antibiotics of AA-896
    Patent number: 6727232
    Abstract: This invention relates to antibiotic compounds AA896 of the formula wherein: R1 is H, aryl, alkyl (C1-C20), —CH2-aryl, —C(O)alkyl(C1-C20), —C(O)NHalkyl(C1-C20), or —C(O)NHaryl; R2 is H, alkyl (C1-C20), —CH2aryl, alkyl (C1-C20) or —C(O)alkyl(C1-C20); R3 is —OH; R2 and R3 may optionally be taken together to form a moiety R4 is alkyl (C1-C20), or aryl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: April 27, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Yang-I Lin, Zhong Li, Gerardo DelaCruz Francisco, Leonard Alexander McDonald
  • 5-(Substituted)-5-(substitutedsulfonyl or sulfanyl) thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
    Patent number: 6716862
    Abstract: The invention relates to compounds of Formula (I) wherein R1, (R2)v, R3 and n are defined in the specification and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: April 6, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Edward James Salaski, Semiramis Ayral-Kaloustian, Joseph William Epstein
  • Substantially pure glycopeptide antibiotics AC-98-1; AC-98-2; AC-98-3; AC-98-4 and AC-98-5
    Patent number: 6713448
    Abstract: The invention provides new substantially pure antibiotics designated AC-98-1, AC-98-2, AC-98-3, AC-98-4 and AC-98-5 derived from the microorganism Streptomyces hygroscopicus.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: March 30, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Guy Thomas Carter, Haiyin He
  • 5-Substituted-3(2H)-furanones useful for inhibition of farnesyl-protein transferase
    Patent number: 6710078
    Abstract: Compounds of Formula (I): wherein R1, R2, R3, X, Y, Z and Q are as defined in the specification which compounds are inhibitors of Ras farnesyl-protein transferase enzyme (FPTase), and useful in treating ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid and processes for the preparation of said compounds of Formula (I).
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: March 23, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Semiramis Ayral-Kaloustian, Irwin Hollander, Ann Aulabaugh
  • Antibiotics AA-896
    Patent number: 6689763
    Abstract: This invention relates to new antibiotics designated AA-896-A1, AA-896-A2, AA-896-A3, AA-896-A4, AA-896-A5, AA-896-A6, AA-896-B1, AA-896-B2, AA-896-B3, AA-896-B4, AA-896-B5, AA-896-B6, AA-896-B7, AA-896-C1, AA-896-C2, AA-896-C3, AA-896-C4, AA-896-C5, AA-896-D1, AA-896-D2, AA-896-D3 and AA-896-D4 derived from the microorganism Streptomyces spp. LL-AA896 which are useful an anti-bacterial agents.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: February 10, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Guy Thomas Carter, Jason Arnold Lotvin, Leonard Alexander McDonald
  • PROCESS IMPROVEMENT IN THE PREPARATION OF (4R, 5S, 6S)-3-[[(2R,3R)-2-[[[(S)-2-AMINO-3-METHYL-1-OXOBUTYL]AMINO]METHYL]TETRAHYDRO-3-FURANYL]THIO]-6-[(R)-1-HYDROXYETHYL]-4-METHYL-7-OXO-1-AZABICYCLO[3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID
    Patent number: 6649756
    Abstract: The invention is a process improvement for producing the carbapenem antibacterial agent (4R, 5S, 6S)-3-[[2R,3R)-2-[[[(S)-2-amino-3-methyl-1-oxobutyl]amino]methyl]tetrahydro-3-furanyl]thio]-6-[R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid by hydrogenation of 4-nitrobenzyl (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-3-{[2R,3R)-2-({[(2S)-3-methyl-2-({[4-nitrobenzyl)oxy]carbonyl}amino)butanoyl]amino}methyl)-tetrahydrofuran-3-yl]thio}-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate in a biphasic solvent mixture comprising a water portion and an organic solvent portion, not containing an acid acceptor.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: November 18, 2003
    Assignee: Wyeth, Five Giralda Farms
    Inventors: Tarek Mansour, Phaik-Eng Sum, Yang-I Lin, Zhong Li
  • Adjuvant and vaccine compositions containing monophosphoryl lipid A
    Patent number: 6635261
    Abstract: The invention pertains to adjuvant and vaccine compositions of monophosphoryl lipid A, sugar and optionally an amine based surfactant, which when frozen and thawed or lyophilized and reconstituted reform a colloidal suspension having a light transmission of greater than or equal to 88% as measured spectrophotometrically.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: October 21, 2003
    Assignee: Wyeth Holdings Corporation
    Inventors: Vincent James LaPosta, John Hayward Eldridge
  • Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
    Patent number: 6605628
    Abstract: This invention relates to a method of using novel 5-(arylsulfonyl)-5-(arylsulfinyl)- and 5-(arylsulfanyl)thiazolidine-2,4-diones of Formula (I), wherein Ar, Ar′, R6, m and n are as defined in the specification as inhibitors of Ras FPTase, and may be used as an alternative to, or in conjunction with, traditional cancer therapy for treating ras- oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: August 12, 2003
    Assignee: Wyeth Holdings Corporation
    Inventors: Semiramis Ayral-Kaloustian, Joseph William Epstein, Gary H. Birnberg, Edward James Salaski, Gloria Jean Macewan, Katherine Cheung
  • Reversal of multidrug resistance in human colon carcinoma cells
    Patent number: 6537964
    Abstract: The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: March 25, 2003
    Assignee: Wyeth Holdings Corporation
    Inventors: Haiyin He, Lee Martin Greenberger
  • 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
    Patent number: 6521618
    Abstract: This invention provides compounds of Formula (I), having the structure where T, Z, X, A, R1, R2a, R2b, R2c, R3, R4, and n are defined herein, or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of osteoporosis and polycystic kidney disease.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: February 18, 2003
    Assignee: Wyeth
    Inventors: Diane Harris Boschelli, Yanong Wang, Frank Charles Boschelli, Dan Maarten Berger, Nan Zhang, Dennis William Powell, Fei Ye, Ayako Yamashita, Frenel Fils DeMorin, Biqi Wu, Hwei-Ru Tsou, Elsebe Geraldine Overbeek-Klumpers, Allan Wissner
  • 2,4,6-trisubstituted pyridines with estrogenic activity and methods for the solid phase synthesis thereof
    Patent number: 6503917
    Abstract: The present invention relates to novel substituted pyridine compounds of Formula (I) wherein the moiety Z, R1, R2 and R3 are as herein defined, having estrogenic activity, to processes for their preparation, to a combinatorial library and solid phase methods for preparing libraries of the compounds, to utilizing libraries of the compounds for drug discovery, to methods of treatment and to pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 1, 2000
    Date of Patent: January 7, 2003
    Assignee: Wyeth, Five Giralda Farms
    Inventors: Chingfan Chiu, Zhilian Tang, John W. Ellingboe
  • 6-(spirocyclopropyl) penicillanic acid 4, 4-dioxides
    Patent number: 6489316
    Abstract: The 6-(spirocyclopropyl)-penicillanic acid 4,4-dioxides of the general Formula (I): as defined herein above which exhibit beta-lactamase inhibiting activity, use of such compounds in combination with beta-lactam antibiotics for inhibiting beta-lactamases, pharmaceutical compositions and processes for preparing such compounds.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: December 3, 2002
    Assignee: American Cyanamid Company
    Inventors: Vincent P. Sandanayaka, Amarnauth S. Prashad